Xeris Biopharma, Inc.

154 articles with Xeris Biopharma, Inc.

• Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris

  8/31/2021

  Glass Lewis Joins ISS in Recommending Strongbridge Shareholders Vote “FOR” Transaction with Xeris Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals

• Xeris Pharmaceuticals Announces Leading Independent Proxy Advisory Firm, ISS, Recommends Xeris Stockholders Vote “FOR” the Transaction With Strongbridge Biopharma

  8/30/2021

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) today announced that a leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that Xeris stockholders vote “FOR” all proposals related to the Company’s transaction with Strongbridge Biopharma plc

• Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke® Kit for the Treatment of Severe Hypoglycemia

  8/23/2021

  Xeris Pharmaceuticals, Inc. today announced that its supplemental new drug application (sNDA) of Gvoke® Kit was approved by the Food and Drug Administration (FDA) for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above.

• Xeris Pharmaceuticals Strengthens Its Patent Estate

  8/19/2021

  Xeris Pharmaceuticals, Inc. today announced that it has recently been granted three new patents relating to its formulation technology platforms.

• Xeris Pharmaceuticals Achieves Unprecedented Levels of Payor Coverage for Gvoke®

  8/13/2021

  Xeris Pharmaceuticals, Inc. today announced the achievement of an important milestone of payor coverage for Gvoke

• Xeris Pharmaceuticals Announces FDA Acceptance of its IND Application for XeriSol™ Levothyroxine (XP-8121) for the Treatment of Hypothyroidism

  8/11/2021

  Xeris Pharmaceuticals, Inc. today announced that the Food and Drug Administration (FDA) has allowed the Investigational New Drug Application (IND) for its XeriSol levothyroxine for hypothyroidism to proceed.

• Xeris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Highlights

  8/5/2021

  Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, announced financial results for the second quarter and first six months ended June 30, 2021, and recent highlights.

• Xeris Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021

  7/29/2021

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that the Company will release its second quarter 2021 financial results before the open of the U.S. financial markets on Thursday, August 5, 2021.

• Xeris Pharmaceuticals Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue

  7/29/2021

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (Xeris) today announced in accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013 (the Irish Takeover Rules) that, as of the close of business on July 28, 2021, Xeris' issued share capital, excluding treasury shares, is comprised of 66,497,370 shares of common stock with a par value of $0.0001 per share.

• Xeris Pharmaceuticals Announces Executive Changes as Part of Its Strategy to Position the Company for Long-Term Commercial Success

  7/28/2021

  Xeris Pharmaceuticals, Inc. announced executive changes as part of its strategy to position the company for long-term commercial success, including the anticipated closing of the Strongbridge Biopharma plc acquisition and evolution to a more commercially driven company.

• Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe

  7/19/2021

  Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo ® in Europe.

• Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 02, 2021

  7/2/2021

  Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable drug formulations, announced that on July 1, 2021, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 80,250 shares of its common stock to 37 new employee under Xeris’ Inducement Equity Plan.

• Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases

  5/24/2021

  Transaction Creates Fast-Growing Biopharmaceutical Company with Two Commercial Assets and Robust Clinical Pipeline with Multiple Near-term Inflection Points

• Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights

  5/13/2021

  Gvoke® quarterly net sales of $8.1 million Record quarterly Gvoke prescription volume Strong cash position of $136.0 million Conference call and webcast today at 8:30 a.m. ET

• Xeris Pharmaceuticals to Webcast Upcoming Presentations

  5/10/2021

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will participate in following upcoming virtual events:

• Xeris Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021

  5/6/2021

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its first quarter 2021 financial results before the open of the U.S. financial markets on Thursday, May 13, 2021

• Xeris Pharmaceuticals Announces Extension of the Interest-Only Period of Its Debt Facility With Oxford Finance and Silicon Valley Bank

  5/6/2021

  Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced that it has entered into an amendment to its existing loan and security agreement with Oxford Finance LLC and Silicon Valley Bank.

• Xeris Pharmaceuticals Receives U.K. MHRA Approval of Ogluo® (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

  4/29/2021

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the United Kingdom’s Medicines and Healthcare Regulatory Agency (MHRA) has approved Ogluo® (glucagon) injection

• Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Apr 01, 2021

  4/1/2021

  Xeris Pharmaceuticals, Inc. announced that on March 31, 2021, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 15,250 shares of its common stock to 10 new employee under Xeris’ Inducement Equity Plan.

• Xeris Pharmaceuticals Announces Pricing of $27.0 Million Registered Direct Offering

  3/11/2021

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the pricing of a registered direct offering of 6,553,398 shares of common stock, par value $0.0001 per share (the “Shares”), to funds managed by Deerfield Management Company, L.P.